Search PubMed⌕ Search

Biomedical subjects

M Murase

Publications and source records attributed to M Murase.

At least 163 records · Page 9Linked to original sources
PubMed1987

Effects of Triton WR 1339 and orotic acid on lipid metabolism in rats.

In order to investigate the effect of hepatic cholesterol flux on biliary bile acids, Triton WR 1339 and orotic acid were administered to rats, and the biliary cholesterol, phospholipids and bile acids were analyzed together with serum lipoproteins and hepatic lipids. Triton, which raised serum very low density lipoprotein and lipid levels and decreased serum high density lipoprotein liver lipid levels, increase the biliary cholic acid group/chenodeoxycholic acid group ratio (CA/CDCA) in the bile without affecting the total amount of bile acids and the other biliary lipids. Orotic acid, which decreased serum lipid and lipoprotein concentrations and increased liver lipid levels, increased the biliary excretion of cholesterol and phospholipids, but produced no significant change in the total amount of bile acids and in the CA/CDCA ratio in bile.

Animals↗
PubMed1987

[Susceptibility of clinical bacterial isolates to aztreonam].

In vitro activities of 7 antimicrobial agents against organisms (474 strains) isolated from patients with various infections in Ehime University Hospital from May to July 1986 were investigated. Summarized results are as follows: 1. Aztreonam (AZT) showed potent activities against Escherichia coli, Citrobacter sp., Klebsiella pneumoniae, Serratia marcescens, Proteus sp., Pseudomonas aeruginosa and Haemophilus influenzae. 2. Antimicrobial activities of AZT were especially superior against Proteus sp. to the third generation cephem antibiotics. 3. Enterobacter sp. seemed more susceptible to AZT than to cephem antibiotics, but minimum inhibitory concentrations of AZT against may isolates of Enterobacter sp. were in wide ranges.

Aztreonam↗
PubMed1987

[Clinical studies of flomoxef in the pediatric field].

Flomoxef (FMOX, 6315-S) was evaluated pharmacologically and clinically in its application to bacterial infections in children. 1. Pharmacokinetics: A bullous intravenous injection of FMOX at 20 mg/kg body weight gave a peak serum concentration of 114.6 +/- 34.4 micrograms/ml in 1 minute after the injection and T1/2 of beta-phase was 0.86 +/- 0.15 hours. 2. Bacteriological effectiveness: MIC of FMOX against Staphylococcus aureus except resistant strains (10(6) cells/ml) was below 0.39 micrograms/ml and against Haemophilus influenzae, Escherichia coli and Klebsiella pneumoniae (10(6) cells/ml) were below 0.78 microgram/ml. 3. Clinical effectiveness: Clinical effectiveness of FMOX was excellent in 14 cases, good in 2 cases and fairly good in 1 case among 17 cases of bacterial infections examined. An increase in eosinophilic leukocytes was observed in 1 case but no other clinical adverse effects were detected. These findings indicate that FMOX is a useful and safe antibiotic as a first choice against bacterial infections in children.

Age Factors↗
PubMed1987

[Clinical studies of cefuzonam in the pediatric field].

Analysis on serum concentrations of cefuzonam (CZON, L-105) in 7 children who received different doses of CZON revealed a dose-response relationship. The half-life of the drug in blood was 0.90 hour. CZON was administered to 17 pediatric patients with bacterial infections. The clinical efficacy rate was 88% (15/17), and the eradication rate of pathogens was 80% (4/5). Only one case of mild diarrhea (1/17) was observed as a side effect associated with CZON.

Adolescent↗